Introduction
============

Based on data emanating from studies on the role of rotavirus in the burden of disease[@R1],[@R2] and local safety and efficacy trials of the rotavirus vaccine[@R3], South Africa decided as the first African country to include the monovalent rotavirus vaccine (Rotarix®, GlaxoSmithKline Biologicals, Rixensart, Belguim) in its national immunization programme, starting in 2008[@R4]. The vaccination consists of two-doses, administered orally at 6 and 14 weeks of age, simultaneously with other vaccines included in the expanded programme on immunization (EPI). The vaccine coverage increased rapidly since 2009 and by 2010, about 67% of children under a year old had received a complete schedule of Rotarix® immunization. The vaccine coverage rate has since increased to more than 90% in some provinces[@R5]. However, rotavirus prevalence and its associated hospitalization inSouth Africa including KwaZulu-Natal (KZN) province[@R6] has raised questions regarding the effectiveness of this vaccine. To ensure that children receive potent and effective vaccines, the vaccine has to be stored at the optimum temperatures while in storage and on transit. However, accidental or inevitable exposure of this vaccine to heat or freezing temperature while in storage or in transit can result in loss of potency as reported previously by Matthias et al[@R7]. The possibility of vaccine exposure to non-optimal temperatures was considered as a factor responsible for the reduced effectiveness of the rotavirus vaccine in middle- and low-income countries. These countries are often characterized by poor road networks and inadequate electricity supply. Poor road networks can expose vaccines to non-optimal temperatures in transit while inadequate electricity supply can also expose the vaccines to temperature fluctuations during storage.

The World Health Organization (WHO) recommended that all vaccines except that for oral polio be kept at 2 to 8°C during in-country distribution[@R8]. However, a poorly maintained cold chain system may expose vaccines to non-optimal temperatures ranging from hot to freezing. Rotavirus vaccine is listed as being affected by cold chain failure[@R8]--[@R12]. Vaccine cold-chain challenges are more frequently seen in low income countries in comparison to high income countries. Consequently, loss of potency may be responsible for the reduced effectiveness of the rotavirus vaccine observed in middle- and low-income countries. We assessed the effect of non-optimal storage temperature on the potency of the monovalent rotavirus vaccine.

Methods
=======

The effect of temperature on the potency of the Rotarix® vaccine was studied. The vaccine was obtained from the central pharmaceutical store of the KwaZulu-Natal Department of Health (DOH). Vaccines were exposed to the average temperatures experienced over the different seasons in KwaZulu-Natal province. The potency was evaluated at 0, 1, 2, 3, 4, 5 and 6 hours. The average seasonal temperatures during 2005 till 2015 were 24°C in spring, 27.3°C in summer, 25.7°C in autumn and 23.3°C in winter[@R13]. The vaccines were also exposed to temperatures of −20°C and −80°C for 12 hours and to 40°C for up to 72 hours. A digital oven and freezers were used to simulate vaccine exposure to heat and freezing temperatures respectively. The potency of vaccines stored at the advised temperature of 2 to 8°C was used as the reference standard.

To quantify the vaccine virus after exposure to the different temperatures, the plaque assay described by Smith et al[@R14], was used with some modifications. Vero cells (ATCC CCL-81) were seeded in wells of a 24-well tissue culture plate at a density of 1 x 10^6^ cells/ml in a volume of 500µl. The culture medium used was Eagle\'s minimum essential medium (EMEM) supplemented with 1% HEPES, 1% L-glutamate and 10% heat-inactivated fetal bovine serum (FBS). The plates were incubated at 37°C in 5% CO~2~ till confluent. The vaccine reference standard and test samples were diluted 1:10 in trypsin/PBS (1:60) and a 1:10 dilution in PBS without trypsin. Eight ten-fold serial dilutions (10-1 to 10-8) were made of each of the trypsinized test samples in EMEM with HEPES and L-glutamate. The dilutions were vortexed for 15 seconds and incubated at room temperature (25°C) for 30 minutes prior to infection.

The culture media was aspirated from the confluent Vero cell monolayer and the cells were washed twice with warm PBS. Vaccine virus infection was performed by inoculating 200µl of each sample into the wells in triplicate. The plates were then placed in a 37°C incubator with 5% CO~2~ for 1 hour. The media was replaced with an agar overlay which contains 1ml of 0.1 % agarosein EMEM with 2% FBS and 1% glutamate. The agarose was allowed to solidify for 15 minutes at room temperature after which the plates were transferred to a 37°C incubator with 5% CO~2~ until plaques were formed. When plaques became visible, the monolayers were fixed by dispensing 1ml of 3.6% formalin on the agar overlay followed by incubation at room temperature for 1 hour. Thereafter, the formalin and agarose were discarded under running water. The monolayers were stained for 3 minutes with crystal violet, washed with running water and air dried. The plaques were counted under an inverted light microscope (Olympus, Tokyo, Japan) at 400x magnification \[[Figure 1 (a)](#F1a){ref-type="fig"} and [(b)](#F1b){ref-type="fig"}\]. The concentration of the initial viral suspension in plaque forming unit per milliliter (PFU/ml) was calculated as: PFU/ml = number of plaques x dilution factor x volume of inoculum per plate.
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According to the manufacturer of the Rotarix® vaccine, the vaccine is potent when it is greater than or equal to 10^6^ of 50% cell culture infective dose (Potency \>10^6^ CCID50). To convert the CCID50 to plaque forming unit per milliliter (PFU/ml), we applied the Poisson distribution (P(k) = e-m x m k/k) and in summary PFU/ml = 0.7 x CCID50. Therefore, 10^6^ CCID50 = 0.7 x 10^6^ PFU/ml = 7 x 10^5^ PFU/ml. Therefore, the vaccine should have a minimum potency \>7 x 10^5^ PFU/ml.

We compared the potency of each of the vaccines exposed todifferent temperatures to that of our reference standard and to the acceptable potency according to the vaccine manufacturer.

Results
=======

On receipt of the vaccine from the central pharmacy store, the potency ranged between 5.2-- 6.8 x 10^10^ PFU/ml with an average of 5.8 x 10^10^ PFU/ml, represented by the horizontal line in [figure 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. The potency of the vaccines after exposure to the average seasonal temperatures in KZN is shown in [figure 2](#F2){ref-type="fig"}. At all temperatures the values obtained were above the minimum potency of 7 x 10^5^ PFU/ml as per manufacturer\'s guidelines. However, these temperatures seem to have an effecton the vaccine potency as most of the values were less than pre-exposure to the seasonal temperatures except those exposed to the average temperature of the autumn season. Exposure to extreme temperatures of 40°C for 3 to 72 hours ([Figure 3](#F3){ref-type="fig"}) did not decrease the potency of the vaccine below the minimum advised value. However, we observed a gradual reduction in potency as the duration of exposure increases. The vaccine potencies after exposure to -20oC and -80oC for 12 hours was 3.5 x 10^10^ PFU/ml and 3.0 x 10^10^ PFU/ml respectively. Although these potencies were less than the potency of the optimally stored vaccines, it was higher than the manufacturer\'s minimum advised value.
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Discussion
==========

The possibility of the Rotarix®vaccine exposure to non-optimal temperatures was considered as a factor responsible for the reduced effectiveness of this rotavirus vaccine in low income countries. This vaccine remained potent after exposure to the seasonal temperatures for 6 hours. Although the potencies at the different seasonal temperatures were lower than the pre-exposure potency except at autumn temperature at some of the time points. The observed higher potency at the 1, 4 and 5 hour time point of this temperature in comparison to the pre-exposed vaccine potency may be explained by a higher quantity of vaccine virus in the vials used at these time points. In addition, exposure to +40°C for 72 hours as well as to −20°C and −80°C for 12 hours was well tolerated. These findings correlate with a similar finding in India where a recently licensed thermostable live attenuated Rotavirus vaccine (ROTASIIL®) was found to withstand temperatures as high as 40°C and 55°C for long- and short-term exposure respectively[@R15]. In addition, the study reported that the vaccine was able to tolerate a temperature shock of being thawed from -20oC to a temperature of 42°C[@R15].

The mechanism for the reduced effectiveness of the Rotarix ® vaccine in middle and low income countries[@R16] in contrast to the observed high effectiveness of this vaccine in high income countries[@R17] is not completely understood. Although possible factors driving these variations in vaccine effectiveness have previously been reported[@R18]. Viral, environmental and host factors were identified as possible determinant of protection elicited by this vaccine[@R18]. Protection from diverse rotavirus strains including non-vaccine genotypes has been reported as a significant characteristic of this vaccine[@R16],[@R19]. However, the mechanism of this vaccine protection against diverse and emerging rotavirus strain is incompletely understood. Environmental enteropathy, a sub-clinical condition affecting the small intestine of children in low income countries was suggested as a factor influencingvaccine effectiveness[@R20]. This condition is characterized by chronic exposure to faecal pathogens due to poor sanitation leading to chronic inflammation of the intestine[@R21]. The presence of maternal antibodies acquired via breast milk has been reported to compromise the effectiveness of the rotavirus vaccine in children[@R22]. In addition, pre-existing serum immunoglobulin G (IgG) was reported to have an inhibitory effect on the immunogenicity of the rotavirus vaccine[@R23].

Limitation of the study
=======================

This study was unable to elucidate reason(s) for the maintained potency of the Rotarix® vaccine after exposure to non-optimal temperatures. In addition, this study only explored the effect of a constant 'adverse' temperature on vaccine potency and not the effect of temperature fluctuations.

Conclusion
==========

The stability of theRotarix® vaccine after exposure to diverse temperatures reflecting potential storageor transit temperatures in some middle- and low-income countries was highlighted in this study. It will be interesting to evaluate the effect of non-optimal temperatures on the vaccine when exposed for a longer period above the time point in our study. Further exploration is needed to draw a firm conclusion on the stability of the Rotarix® vaccine post exposure to more non-optimal temperatures. This is the only independent study on thermostability of the monovalent Rotarix® vaccine.
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